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Progress in understanding the role of dystrophin raises promising hopes 
for a treatment for Duchenne muscular dystrophy. In addition, great 
improvements have been made in the ability to diagnose this disease using 
simple molecular methods. 
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Introduction 
More than 4 years have passed since the gene responsible 
for Duchenne/Becker muscular dystrophy (DMD/BMD) 
was identified. Progress in understanding this gene and 
its role in disease has followed at a breathtaking pace, 
and the rapidly emerging information has been summa- 
rized in at least three reviews in the past year alone [l-3]. 
This article is intended to highlight only the most sig- 
nificant advances made in the past year, and focuses on 
three specific areas: developing efficient and cost-effec- 
tive methods for diagnosis and carrier detection of DMD; 
understanding the role of the DMD gene product, dys- 
trophin; and developing approaches to a treatment or 
cure for the disease. In the absence of a treatment, dis- 
ease diagnosis and genetic counseling remain the most 
concrete example of how recent progress is of benefit to 
patients. The understanding of how defects in the dys- 
trophin gene lead to various manifestations of the dis- 
ease is critical for an understanding of the role played 
by dystrophin in various tissue types, which, in turn, is 
important for an intelligent approach to developing and 
implementing treatments for DMD. 
Diagnosis of DMD 
Deletion mutations account for the majority of all 
cases of DMD, but the enormous size of the locus 
(> 2.3 x 106b p ) h as prevented any simple assay of the 
integrity of the gene or even a detailed understanding 
of the gene structure. Den Dunnen et al. [4*] have re- 
ported a detailed analysis that has retined knowledge of 
the gene structure, particularly in the deletion-prone cen- 
tral region. Boyce et al. have localized and characterized 
the extreme 5’ end of the locus, corresponding to the 
promoter region used predominantly in brain tissue [ 5*]. 
This additional knowledge of the gene structure is criti- 
cal for DNA-based diagnosis of DMD. Two groups have 
reported refinements of tests for the detection of dele- 
tions using the polymerase chain reaction (PCR) [6-,?I. 
These assays can be used to scan for deletions in the 
gene, enabling direct detection of the majority of cases 
with a simple assay requiring one day to perform. Partial 
gene duplication mutations have been shown to account 
for an additional 5-10% of DMD cases, and knowledge 
of the gene structure has facilitated analysis of the effects 
of these mutations and their likely origin [8*]. 
Approximately 30% of DMD cases result from subtle mu- 
tations not readily detectable with current methodolo- 
gies, and family studies involving these cases are per- 
formed using linkage analysis of polymorphic loci that 
both lie within and flank the dystrophin gene. PCR 
promises to greatly facilitate these assays, and is soon 
likely to be the only technique needed for the diagno- 
sis of the vast majority of cases. Two groups have re- 
ported PCR assays that enable efficient haplotyping us- 
ing highly informative microsatellite repeat markers at ei- 
ther end of the locus [9,10*]. The dystrophin gene has 
been shown to be a very recombinagenic locus, which 
increases the possibility of making an erroneous diagno- 
sis based upon linkage analysis [ 11.1. The identification 
of additional microsatellite repeats throughout the central 
region of the gene now makes it possible to track these 
recombination events and to perform accurate haplotyp- 
ing on most DMD families (J Chamberlain, P Clemens, 
CT Caskey, unpublished data). 
Two groups have reported an exciting alternative to DNA- 
based diagnosis, whereby the dystrophin mRNA is am- 
plified to allow assessment of its size, again using PCR 
[12*,13*]. These assays have the advantage of being able 
to detect most structural rearrangements of the gene in 
affected males as well as in many carrier females, but al- 
though they require nothing more than a blood sample, 
these tests are not as simple to perform as the DNA as- 
says. Finally, tests that examine the integrity of the dys- 
trophin protein directly have been refined, and antibod- 
ies can now be used to identify the size of a defective pro- 
tein species produced in dystrophic muscle [14*]. This 
information can also be used to understand the severity 
of the disease in relation to particular mutations. 
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The function of dystrophin 
Perhaps the most exciting development of the past year 
was the increased understanding of the role dystrophin 
plays in normal muscle tissue. Ervasti et al. reported 
the identification of a protein complex associated with 
dystrophin [ 15**]. These dara indicate that dystrophin 
may play an important role in regulating the activity 
or function of specific membrane proteins. Although 
it is not yet clear what this function may be, two re- 
ports of altered calcium channels in dystrophic muscle 
strongly implicate a role for dystrophin in calcium trans- 
port and/or homedstasis [1@*,17**]. It will be exciting 
to learn whether the membrane proteins identified by Er- 
vasti et al. [IV=] either regulate or act as calcium chan- 
nels. It has been thought by many researchers that dys- 
trophin plays a structural or mechanical role in reinforc- 
ing the sarcolemma; now it seems likely that the protein 
plays a dual role, regulating the activity of membrane pro- 
teins.a.5 well as acting as a structud component of the 
membrane. Direct evidence for a structural role comes 
not only from previous antibody experiments but also 
from a recent report that demonstrated that dystrophic 
muscle cells are unusually sensitive to osmotic shock 
[18*]. A detailed report on the likely structure of dys- 
troptiin supports the concept of a structural role [ 19’1, 
and has implications for the effects of internal truncations 
of the protein that lead to mild phenotypes. A patient 
reported by England et a/. [20-l was found to lack al- 
most 50% of the dystrophin amino acid sequence, yet 
displayed a surprisingly mild phenotype. The ability to 
correlate domains of the protein that are essential or non- 
essential for proper functioning of dystrophin may fa- 
cilitate the design of vectors for gene therapy (see be- 
low). Finally, whereas studies of the role of dystrophin 
have focused mainly upon skeletal muscle, Lidov et al. 
[21**] identified the location of at least one isoform of 
dystrophin within brain tissue. The observed brain lo- 
calization implies that dystrophin plays a unique role in 
nerve cells, and it will be important to determine which 
proteins are associated with dystrophin in non-muscle tis- 
sues. 
Therapy for DMD 
Despite recent progress on many fronts, there is still no 
treatment or cure for DMD. At least two areas of study 
appear promising, and both aim at directly replacing 
the synthesis of dystrophin in affected tissues. Myoblast 
transplantation therapy has been extensively discussed as 
a method to provide skeletal muscle with normal dys- 
trophin, and was the focus of an international confer- 
ence in 1989 that brought together many leading muscle 
researchers. The proceedings of this meeting have been 
published in a book that addresses the problems, hopes 
and challenges facing investigators hoping to replace the 
myogenic stem cell population with donor myoblasts in 
dystrophic skeletal muscle [22*]. Although these expen- 
ments have been pioneered in mouse model systems, the 
urgency of Unding a cure has prompted several groups 
to launch human trials with minimal animal experimenta- 
tion, To date only preliminary results have been reported 
[23*], and it remains to be demonstrated whether this 
technique is feasible. 
An even more untested approach involves gene replace- 
ment therapy. As the dystrophin gene is of such enor- 
mous size, most efforts are focused upon developing 
methods to deliver dystrophin ‘minigenes’ to affected tis- 
sues. Lee et al [24.-l have reported the construction 
and expression of a dystrophin minigene vector that was 
made using a fuU length cDNA clone, and that produces 
normal dystrophin when transferred into a variety of ceU 
types. Directing the expression of such a vector will re- 
quire appropriate tissue-specific-promoter elements, and 
I&nut et al. [25*] have identiIied and characterized the 
major dystrophin gene promoter, which is predominantly 
used in muscle. This work raises the possibility of us- 
ing the endogenous dystrophin promoter for minigene 
expression in therapeutic trials. Development of meth- 
ods by which minigenes could be delivered to patients 
will require further research, although a surprisingly sim- 
ple method was reported by Wolff et al. [26-l. These 
authors showed that plasmid DNA injected directly into 
muscle could be incorporated into the tissue and ex- 
pressed for at least several months’ duration. 
Although both myoblast and gene therapy are extremely 
experimental approaches for treating DMD, research in 
these areas is encouraging. Five years ago there was lit- 
tle reason to expect a quick breakthrough, and years of 
additional research certainly remain. In spite of this, how- 
ever, continued study of the structure, function, and ex- 
pression of the dystrophin gene, together with the devel- 
opment of approaches for dystrophin delivery to affected 
tissues, do raise hopes for the successful treatment of this 
devastating and relativety common genetic disease. 
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